Cargando…

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review

INTRODUCTION: Maximal androgen blockade (mab) versus castration alone in patients with metastatic prostate cancer has been extensively evaluated in randomized trials. The inconsistent results have led to the publication of multiple meta-analyses. The present review examines the evidence from meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukka, H., Waldron, T., Klotz, L., Winquist, E., Trachtenberg, J.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891181/
https://www.ncbi.nlm.nih.gov/pubmed/17576447
_version_ 1782133738738548736
author Lukka, H.
Waldron, T.
Klotz, L.
Winquist, E.
Trachtenberg, J.
author_facet Lukka, H.
Waldron, T.
Klotz, L.
Winquist, E.
Trachtenberg, J.
author_sort Lukka, H.
collection PubMed
description INTRODUCTION: Maximal androgen blockade (mab) versus castration alone in patients with metastatic prostate cancer has been extensively evaluated in randomized trials. The inconsistent results have led to the publication of multiple meta-analyses. The present review examines the evidence from meta-analytic reports to determine whether mab using agents such as flutamide, nilutamide, and cyproterone acetate (cpa) is associated with a survival advantage. METHODS: We conducted a systematic review of the literature (medline, embase, and the Cochrane Library through July 2004; cancerlit through October 2002) for meta-analyses that compared mab with castration alone in previously untreated men with metastatic prostate cancer (D1 or D2, N+/M0 or M1). Two reviewers selected papers for eligibility; disagreement was resolved by all the authors through consensus. RESULTS: The literature search identified six meta-analyses that met the eligibility criteria of the review. Two of those reports were based on individual patient data (ipd), and four were based on data from the published literature. All six meta-analyses pooled data on overall survival. The best evidence came from the largest meta-analysis, conducted by the Prostate Cancer Trialists Collaborative Group and based on ipd (8725 patients) from 27 trials. That analysis detected no difference in overall survival between mab and castration alone at 2 or 5 years. However, a subgroup analysis showed that mab with nonsteroidal anti-androgens (nsaas) was associated with a statistically significant improvement in 5-year survival over castration alone (27.6% vs. 24.7%; p = 0.005). The combination of mab with cpa, a steroidal anti-androgen, was associated with a statistically significant increased risk of death (15.4% vs. 18.1%; p = 0.04). Compared with castration alone, mab was associated with more side effects (that is, gastrointestinal, endocrine function) and reduced quality of life in domains related to treatment symptoms and emotional functioning. CONCLUSIONS: The small survival benefit conferred by mab with nsaa is of questionable clinical significance given the added toxicity and concomitant decline in quality of life observed in patients treated with mab. Therefore, combined treatment with flutamide or nilutamide should not be routinely offered to patients with meta-static prostate cancer beyond the purpose of blocking testosterone flare. Monotherapy, consisting of orchiectomy or the administration of a luteinizing hormone–releasing hormone agonist is recommended as standard treatment.
format Text
id pubmed-1891181
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-18911812007-06-18 Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review Lukka, H. Waldron, T. Klotz, L. Winquist, E. Trachtenberg, J. Curr Oncol Review Article INTRODUCTION: Maximal androgen blockade (mab) versus castration alone in patients with metastatic prostate cancer has been extensively evaluated in randomized trials. The inconsistent results have led to the publication of multiple meta-analyses. The present review examines the evidence from meta-analytic reports to determine whether mab using agents such as flutamide, nilutamide, and cyproterone acetate (cpa) is associated with a survival advantage. METHODS: We conducted a systematic review of the literature (medline, embase, and the Cochrane Library through July 2004; cancerlit through October 2002) for meta-analyses that compared mab with castration alone in previously untreated men with metastatic prostate cancer (D1 or D2, N+/M0 or M1). Two reviewers selected papers for eligibility; disagreement was resolved by all the authors through consensus. RESULTS: The literature search identified six meta-analyses that met the eligibility criteria of the review. Two of those reports were based on individual patient data (ipd), and four were based on data from the published literature. All six meta-analyses pooled data on overall survival. The best evidence came from the largest meta-analysis, conducted by the Prostate Cancer Trialists Collaborative Group and based on ipd (8725 patients) from 27 trials. That analysis detected no difference in overall survival between mab and castration alone at 2 or 5 years. However, a subgroup analysis showed that mab with nonsteroidal anti-androgens (nsaas) was associated with a statistically significant improvement in 5-year survival over castration alone (27.6% vs. 24.7%; p = 0.005). The combination of mab with cpa, a steroidal anti-androgen, was associated with a statistically significant increased risk of death (15.4% vs. 18.1%; p = 0.04). Compared with castration alone, mab was associated with more side effects (that is, gastrointestinal, endocrine function) and reduced quality of life in domains related to treatment symptoms and emotional functioning. CONCLUSIONS: The small survival benefit conferred by mab with nsaa is of questionable clinical significance given the added toxicity and concomitant decline in quality of life observed in patients treated with mab. Therefore, combined treatment with flutamide or nilutamide should not be routinely offered to patients with meta-static prostate cancer beyond the purpose of blocking testosterone flare. Monotherapy, consisting of orchiectomy or the administration of a luteinizing hormone–releasing hormone agonist is recommended as standard treatment. Multimed Inc. 2006-06 /pmc/articles/PMC1891181/ /pubmed/17576447 Text en 2006 Multimed Inc.
spellingShingle Review Article
Lukka, H.
Waldron, T.
Klotz, L.
Winquist, E.
Trachtenberg, J.
Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title_full Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title_fullStr Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title_full_unstemmed Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title_short Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
title_sort maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891181/
https://www.ncbi.nlm.nih.gov/pubmed/17576447
work_keys_str_mv AT lukkah maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT waldront maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT klotzl maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT winquiste maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT trachtenbergj maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview
AT maximalandrogenblockadeforthetreatmentofmetastaticprostatecancerasystematicreview